The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
O6-methylguanine-DNA-methyltransferase (MGMT) has emerged as a relevant predictor of therapeutic response and good prognosis in patients with glioblastoma (GBM). Transcriptionally active MGMT rapidly removes the alkyl adducts, preventing the formation of cross-links and thereby causing resistance to...
Main Authors: | Veronica Villani, Beatrice Casini, Andrea Pace, Luca Prosperini, Carmine M. Carapella, Antonello Vidiri, Alessandra Fabi, Mariantonia Carosi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2015/604719 |
Similar Items
-
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
by: Mirri Maria, et al.
Published: (2009-03-01) -
Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma
by: Sophie Richard, et al.
Published: (2020-09-01) -
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
by: Fatih Incekara, et al.
Published: (2020-05-01) -
The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
by: Fatih Incekara, et al.
Published: (2020-07-01) -
Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study
by: Iole Cordone, et al.
Published: (2017-04-01)